TTPHinactive

TETRAPHASE PHARMACEUTICALS INC

Healthcare·Oncology·Commercial
OncologyInfectious DiseaseRespiratory

TETRAPHASE PHARMACEUTICALS INC (TTPH): 6 pipeline candidates · ~7 mo cash runway · 4 clinical trials. Updated within the last hour.

8.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway2.0

7.3 months

Financial Health10.0

0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for TETRAPHASE PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$26.1M

Quarterly Burn

$11.2M

Runway

7.3 mo

Revenue

$1.8M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jan 2027
Today~8 mo out
Catalyst within runway

Pipeline (6 candidates)

DrugPhase
eravacyclinePhase 3
iv eravacyclinePhase 3
tp-271Phase 1
tp-2846Preclinical
tp-6076Phase 1
xeravaApproved
4 clinical trials·1 FDA decision

Frequently asked questions

How many drug candidates are in TETRAPHASE PHARMACEUTICALS INC's pipeline?

TETRAPHASE PHARMACEUTICALS INC (TTPH) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is TETRAPHASE PHARMACEUTICALS INC's lead drug candidate?

TETRAPHASE PHARMACEUTICALS INC's most advanced tracked candidate is eravacycline (Phase 3) for Complicated Intra-abdominal Infections (cIAI).

What is TETRAPHASE PHARMACEUTICALS INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, TETRAPHASE PHARMACEUTICALS INC has approximately 7.3 months of cash runway.

Get the full picture on TETRAPHASE PHARMACEUTICALS INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar